IMR Press / CEOG / Volume 30 / Issue 2-3 / pii/2003034

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report

Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: A case report and review of the literature

Show Less
1 Department of Obstetrics and Gynecology, University of Gaziantep, Medical School, Gaziantep (Turkey)
Clin. Exp. Obstet. Gynecol. 2003, 30(2-3), 151–152;
Published: 10 June 2003
Abstract

A combination of a paclitaxel and platinum analog is currently the standard first-line chemotherapy for women with ovarian cancer, with response rates of 20-37%. As patients who relapse have a poor prognosis and treatment options are limited, there is an urgent need to develop new agents with novel mechanisms of action for use as a second-line, non-cross-resistant chemotherapy in ovarian cancer. In this report, we describe a patient with platinum/paclitaxel-refractory ovarian cancer who received topotecan and reached long­term stabilization of her disease. The patient was administered 1.5 mg/m2 topotecan for five days in 17 cycles. She was also given granulocyte colony-stimulating factor (G-CSF) support to prevent severe granulocytopenia; no hematologic toxic effect was expe­rienced. Her quality of life was good throughout the treatment, and also her daily activities were unaffected.

Keywords
Ovarian cancer
Topotecan
Prolonged stabilization
Share
Back to top